Objective

The task force’s goal is to provide recommendations on reporting and evaluating the risk of bias of systematic reviews with cost or cost-effectiveness outcomes. The recommendations will serve for reviews with various objectives (variability in outcomes, quality of evidence or methods, or research gaps estimation) and will be applicable to summaries of economic evidence assessed either independently or within clinical reviews.

Rationale

The task force report will fill a gap in guidance on assessing the reporting and risk of bias in systematic reviews with cost and cost-effectiveness outcomes and propose a checklist for reviews of varying scope.  With the increasing interest in systematic reviews of economic evaluations, and the current lack of an appropriate instrument to evaluate and judge their quality, there is a significant need for ISPOR good practices on this topic.  It is a priority for the health technology assessment (HTA) field and its respective stakeholders. 

These recommendations and checklist will be important for decision makers, researchers, and producers of health technologies.  The growing number of systematic reviews with an economic component provides coherent evidence on cost-effectiveness outcomes.  However, the diversity of methods and outcomes of these reviews make it difficult for decision makers to use this summarized information most effectively. 

Researchers can improve the reporting and quality of their study and to evaluate reporting and quality of systematic reviews conducted by other teams. Emerging systematic reviews with cost and cost-effectiveness components may guide producers of health technologies on pricing, resource allocation, and economic models, ultimately contributing to market access strategies conditional on the premise that the quality of these reviews is trustworthy.

Jeremy Goldhaber-Fiebert

Jeremy Goldhaber-Fiebert

Associate Professor
CA, United States
Lena Mandrik

Lena Mandrik, MSc MPH

Research Fellow, University of Sheffield
YOR, Great Britain
JL Severens

JL Severens, PhD

Erasmus University Rotterdam
ZH, Netherlands

ARIEL BARDACH, MSc PhD MD

Researcher, IECS - Instituto de Efectividad Clínica y Sanitaria Asociación Civil
Argentina

Salah Ghabri, PhD MD

Health Economist/Project coordinator, French National Authority for Health (HAS)
France

Candyce Hamel

Ottawa Hospital Research Institute
Canada

Cristina Masseria, MSc PhD

Methods and Capabilities Lead, Pfizer
NY, United States

Tim Mathes

Witten / Herdecke University,
Germany

Ghabri Salah, PhD

RESPONSABLE BIOSTATISTIQUE, Keyrus biopharma
France

Luke Vale

Newcastle University
United Kingdom

Torbjørn Wisløff, MSc MASc BSc

Senior statistician, NOKC
Norway
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×